Compare T-Mobile Us Inc (TMUS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Viatris Inc — how do they compare? T-Mobile Us Inc trades at $190.25 (market cap $211.72B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: T-Mobile Us Inc is far larger — about 10.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| TMUS | VTRS | |
|---|---|---|
Market Cap | $211.72B | $19.79B |
Sector | Media | Health |
52-Week High | $259.01 | $17.39 |
52-Week Low | $167.65 | $8.74 |
Enterprise Value | $329.42B | $32.00B |
Dividend Yield | 2.09% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile (TMUS) trades at $190.64, down 0.93% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings near 85. The company demonstrates robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion, though profit margins have moderated from 13.92% in 2024 to 12.44% in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending.
T-Mobile presents a compelling growth story in telecom with strong analyst support (83% buy ratings) and a $237.40 consensus price target implying 25% upside. Key risks include increasing debt-to-asset ratios (39.35% in 2025) and competitive pressures from satellite internet providers. The stock's current valuation at 20.79 P/E appears reasonable given growth prospects, though investors should monitor execution on subscriber and broadband growth targets.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
